Caracterización clínica, asesoramiento genético y análisis genético molecular del gen HTT en núcleos familiares en riesgo para eh en el departamento del Atlántico y otras poblaciones del Caribe Colombiano

datacite.rightshttp://purl.org/coar/access_right/c_f1cf
dc.contributor.advisorYáñez Torregrosa, Zuleima Isabel
dc.contributor.authorYáñez Torregrosa, Javier Antonio
dc.date.accessioned2025-12-12T14:18:50Z
dc.date.available2025-12-12T14:18:50Z
dc.date.issued2025
dc.description.abstractLa Enfermedad de Huntington de Huntington (EH) es un trastorno neurodegenerativo autosómico dominante causado por la expansión del triplete CAG en el gen HTT (4p16.3), que produce una progresiva alteración motora, cognitiva y psiquiátrica. Aunque está reconocida como una enfermedad huérfana en Colombia, persisten profundas brechas en diagnóstico molecular, acceso a asesoramiento genético y atención especializada, especialmente en el Caribe colombiano, donde existen poblaciones históricamente afectadas y con transmisión intrafamiliar sostenida. El objetivo de este estudio fue caracterizar clínicamente a los individuos en riesgo, evaluar sus condiciones socio epidemiológicas y realizar el análisis molecular del gen HTT para determinar la distribución de repeticiones CAG, integrando además un proceso formal de asesoramiento genético dirigido a familias de los departamentos del Atlántico y Magdalena. Se incluyeron 59 participantes pertenecientes a 13 núcleos familiares con antecedente confirmado o presunto de EH. La caracterización clínica permitió identificar manifestaciones motoras, cognitivas y psiquiátricas consistentes con fases tempranas y avanzadas de la enfermedad, coherentes con la literatura según la cual los síntomas pueden iniciarse décadas antes del diagnóstico definitivo. Asimismo, se documentaron síntomas neuropsiquiátricos premotores, cuya presencia temprana puede anticipar la expansión patológica en personas presintomáticas. El componente socio epidemiológico evidenció vulnerabilidad estructural en las familias evaluadas: materiales de vivienda de bajo costo, hacinamiento, exposición a zonas de riesgo, empleos informales, limitaciones económicas y barreras de acceso al sistema de salud. Estos hallazgos son consistentes con estudios previos en comunidades afectadas del Caribe colombiano y explican en parte la continuidad silenciosa de la enfermedad entre generaciones.spa
dc.description.abstractHuntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat in the HTT gene, leading to progressive motor, cognitive, and psychiatric decline. Although HD is officially recognized as a rare disease in Colombia, significant gaps remain in molecular diagnosis, genetic counseling, and specialized clinical care, especially in the Caribbean region, where several high-risk families have been historically identified. This study conducted clinical characterization, socio epidemiological assessment, and CAG repeat molecular analysis in 59 individuals from 13 families with confirmed or suspected HD in the departments of Atlántico and Magdalena. Clinical findings revealed motor and neuropsychiatric features consistent with early and advanced stages of the disease. Socio epidemiological evaluations showed structural vulnerability, limited access to health services, and socioeconomic constraints affecting disease management. Molecular analysis identified normal, intermediate, reduced penetrance, and fully penetrant alleles, supporting intergenerational instability and anticipation. Genetic counseling followed international protocols, improving understanding of inheritance, emotional preparedness, and reproductive decision-making. This integrative approach provides essential evidence for improving diagnostic pathways, public health strategies, and genetic counseling services for HD in the Colombian Caribbean and establishes a foundation for future research.eng
dc.format.mimetypepdf
dc.identifier.urihttps://hdl.handle.net/20.500.12442/17200
dc.language.isospa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias Básicas y Biomédicasspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationaleng
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectEnfermedad de Huntingtonspa
dc.subjectAsesoramiento genéticospa
dc.subjectRepeticiones CAGspa
dc.subjectAnálisis molecularspa
dc.subjectCaribe colombianospa
dc.subject.keywordsHuntington’s diseaseeng
dc.subject.keywordsGenetic counselingeng
dc.subject.keywordsCAG repeatseng
dc.subject.keywordsMolecular analysiseng
dc.subject.keywordsColombian Caribbeaneng
dc.titleCaracterización clínica, asesoramiento genético y análisis genético molecular del gen HTT en núcleos familiares en riesgo para eh en el departamento del Atlántico y otras poblaciones del Caribe Colombianospa
dc.type.driverinfo:eu-repo/semantics/other
dc.type.spaOtros
dcterms.referencesHuntington T, Macdonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6).eng
dcterms.referencesCardoso F. Huntington Disease and Other Choreas. Vol. 27, Neurologic Clinics. 2009.eng
dcterms.referencesDevadiga SJ, Bharate SS. Recent developments in the management of Huntington's disease. Vol. 120, Bioorganic Chemistry. 2022.eng
dcterms.referencesMedina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta- Analysis. Vol. 37, Movement Disorders. 2022.eng
dcterms.referencesMedina Escobar A, Pringsheim T, Gautreau S, Rivera-Duarte JD, Amorelli G, Cornejo-Olivas M, et al. Epidemiology of Huntington's disease in Latin America: A Systematic Review and Meta-Analysis. Mov Disord. 2024 Nov;39(11):1907–21.eng
dcterms.referencesWalker RH, Gatto EM, Bustamante ML, Bernal-Pacheco O, Cardoso F, Castilhos RM, et al. Huntington's disease-like disorders in Latin America and the Caribbean. Vol. 53, Parkinsonism and Related Disorders. 2018.eng
dcterms.referencesDaza B, Cajaffa RH, Arteta BJH, et al. Estudio Neuroepidemiológico en Juan de Acosta (Atlántico-Colombia) Julio de 1989 a Julio de 1991. Acta Medica Colombiana. 1992:17:324.spa
dcterms.referencesEcheverría E. El desarrollo social en la comunidad de Juan de Acosta afectada por la enfermedad de Huntington. Atlántico (Colombia): Documento institucional; 2009.spa
dcterms.referencesCampo M, Baute L. Procesos humanitarios en comunidades afectadas por la Enfermedad de Huntington en la Región Caribe Colombiana. Fundación Colombiana de Comunidades Vulnerables de Colombia (FUNCOVULC). 2013.spa
dcterms.referencesRamos AR, Paiva T, Almeida L. Huntington’s disease: Premotor phase. Neurodegener Dis. 2017;17(6):313-22.eng
dcterms.referencesKachian ZR, Cohen-Zimerman S, Bega D, Gordon B, Grafman J. Suicidal ideation and behavior in Huntington's disease: Systematic review and recommendations. Vol. 250, Journal of Affective Disorders. 2019.eng
dcterms.referencesVarela Londoño LE, Giraldo Mora CV, León Gañan J, Arias Valencia MM. La enfermedad de Huntington: una difícil relación entre los enfermos y el derecho a la salud en Colombia. Revista Ciencias de la Salud. 2021;19(2).spa
dcterms.referencesOosterloo M, Touze A, Byrne LM, Achenbach J, Aksoy H, Coleman A, et al. Clinical Review of Juvenile Huntington’s Disease. J Huntingtons Dis. 2024 Jul 2;13(2):149–61.eng
dcterms.referencesCongreso de la República de Colombia. Ley 1392 de 2010. Gaceta oficial 2010.spa
dcterms.referencesCongreso de Colombia. Ley 1438 de 2011. Congreso de Colombia. 2011;4.spa
dcterms.referencesProtocolo de Vigilancia en salud pública. Enfermedades Huérfanas - Raras. 2024 Aug.spa
dcterms.referencesMinisterio de Salud y de Protección Social. Resolución 0023 de 2023. Colombia; Jan 4, 2023 p. 1–42.spa
dcterms.referencesInstituto Nacional de Salud (INS). Informe de Evento de Enfermedades Huérfanas. Periodo epidemiológico XII de 2024. 2024.spa
dcterms.referencesJiang A, Handley RR, Lehnert K, Snell RG. From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research. Vol. 24, International Journal of Molecular Sciences. 2023.eng
dcterms.referencesCorte Constitucional de Colombia. Sentencia C-055 de 2022. Colombia. 2022;(i).spa
dcterms.referencesAndhale R, Shrivastava D. Huntington's Disease: A Clinical Review. Cureus. 2022 Aug 27;eng
dcterms.referencesNance MA. Genetics of Huntington disease. In 2017. p. 3–14.eng
dcterms.referencesBastepe M, Xin W. Huntington Disease: Molecular Diagnostics Approach. Curr Protoc Hum Genet. 2015 Oct 6;87(1).eng
dcterms.referencesStoker TB, Mason SL, Greenland JC, Holden ST, Santini Huntington's disease: diagnosis and management. Pract Neurol. 2022 H, Barker RA. Feb;22(1):32–41.eng
dcterms.referencesRoss CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011 Jan;10(1):83–98.eng
dcterms.referencesGusella JF, Lee JM, Macdonald ME. Huntington's disease: Nearly four decades of human molecular genetics. Vol. 30, Human Molecular Genetics. 2021.eng
dcterms.referencesSathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A. 2013;110(6).eng
dcterms.referencesMorigaki R, Goto S. Striatal vulnerability in huntington's disease: Neuroprotection versus neurotoxicity. Vol. 7, Brain Sciences. 2017.eng
dcterms.referencesSerranilla M, Pressey JC, Woodin MA. Restoring Compromised Cl- in D2 Neurons of a Huntington's Disease Mouse Model Rescues Motor Disability. The Journal of Neuroscience. 2024 Dec 11;44(50):e0215242024.eng
dcterms.referencesLee JM, Correia K, Loupe J, Kim KH, Barker D, Hong EP, et al. CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset. Cell. 2019;178(4).eng
dcterms.referencesPearson CE, Tam M, Wang YH, Montgomery SE, Dar AC, Cleary JD, et al. Slipped-strand DNAs formed by long (CAG)-(CTG) repeats: Slipped- out repeats and slip-out junctions. Nucleic Acids Res. 2002;30(20).eng
dcterms.referencesCubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C, et al. Clinical manifestations of homozygote allele carriers in Huntington disease. Neurology. 2019;92(18).eng
dcterms.referencesLee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, et al. CAG repeat expansion in Huntington disease determines age on onset in a fully dominant fashion. Neurology. 2012;78(10).eng
dcterms.referencesYescas P, Rasmussen A, Ochoa A, Macias R, Ruiz I, Suastegui R. Homozygosity in Huntington's disease: new ethical dilemma caused by molecular diagnosis. Clin Genet. 2002;61(6).eng
dcterms.referencesPapadopoulou AS, Gomez-Paredes C, Mason MA, Taxy BA, Howland D, Bates GP. Extensive Expression Analysis of Htt Transcripts in Brain Regions from the zQ175 HD Mouse Model Using a QuantiGene Multiplex Assay. Sci Rep. 2019;9(1).eng
dcterms.referencesHughes AC, Mort M, Elliston L, Thomas RM, Brooks SP, Dunnett SB, et al. Identification of novel alternative splicing events in the huntingtin gene and assessment of the functional consequences using structural protein homology modelling. J Mol Biol. 2014;426(7).eng
dcterms.referencesRuzo A, Ismailoglu I, Popowski M, Haremaki T, Croft GF, Deglincerti A, et al. Discovery of novel isoforms of Huntington reveals a new hominid- specific exon. PLoS One. 2015;10(5).eng
dcterms.referencesSchilling J, Broemer M, Atanassov I, Duernberger Y, Vorberg I, Dieterich C, et al. Deregulated Splicing Is a Major Mechanism of RNA-Induced Toxicity in Huntington's Disease. J Mol Biol. 2019;431(9).eng
dcterms.referencesSaudou F, Humbert S. The Biology of Huntingtin. Vol. 89, Neuron. 2016.eng
dcterms.referencesSeefelder M, Kochanek S. A meta-analysis of transcriptomic profiles of Huntington's disease patients. PLoS One. 2021;16(6 June).eng
dcterms.referencesGraham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, et al. Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin. Cell. 2006;125(6).eng
dcterms.referencesWaldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, Arbez N, et al. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. Journal of Neuroscience. 2012;32(1).eng
dcterms.referencesSeefelder M, Klein FAC, Landwehrmeyer B, Fernández-Busnadiego R, Kochanek S. Huntingtin and Its Partner Huntingtin-Associated Protein 40: Structural and Functional Considerations in Health and Disease. Vol. 11, Journal of Huntington's Disease. 2022.eng
dcterms.referencesPalidwor GA, Shcherbinin S, Huska MR, Rasko T, Stelzl U, Arumughan A, et al. Detection of alpha-rod protein repeats using a neural network and application to huntingtin. PLoS Comput Biol. 2009;5(3).eng
dcterms.referencesSchaefer MH, Fontaine JF, Vinayagam A, Porras P, Wanker EE, Andrade- Navarro MA. Hippie: Integrating protein interaction networks with experiment based quality scores. PLoS One. 2012;7(2).eng
dcterms.referencesGuo Q, Huang B, Cheng J, Seefelder M, Engler T, Pfeifer G, et al. The cryo-electron microscopy structure of huntingtin. Nature. 2018;555(7694).eng
dcterms.referencesBiagioli M, Ferrari F, Mendenhall EM, Zhang Y, Erdin S, Vijayvargiya R, et al. Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. Hum Mol Genet. 2015;24(9).eng
dcterms.referencesWändel P, Fredrikson S, Carlsson AC, Li X, Sundquist J, Sundquist K. Huntington's disease among immigrant groups and Swedish-born individuals: a cohort study of all adults 18 years of age and older in Sweden. Neurological Sciences. 2021;42(9).eng
dcterms.referencesKay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, et al. The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2018;177(3).eng
dcterms.referencesEl Pilón. https://elpilon.com.co/costa-atlantica-segunda-region-con- mayor-numero- de-pacientes-con-mal-de-san-vito/. 2017. Costa Atlántica, segunda región con mayor numero de pacientes con ‘mal de San Vito.’spa
dcterms.referencesConsultorsalud. https://consultorsalud.com/el-mayor-numero-de- pacientes-con- huntington-esta-en-la-costa-atlantica/. 2017. El mayor número de pacientes con Huntington está en la Costa Atlántica.spa
dcterms.referencesHarper PS. The epidemiology of Huntington’s disease. Vol. 89, Human Genetics 1992.eng
dcterms.referencesApolinário TA, Rodrigues DC, Lemos MB, Paiva CLA, Agostinho LA. Distribution of the htt gene a1 and a2 haplotypes worldwide: A systematic review. Vol. 18, Clinical Medicine and Research. 2020.eng
dcterms.referencesWarby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, et al. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. European Journal of Human Genetics. 2011;19(5).eng
dcterms.referencesBaine FK, Kay C, Ketelaar ME, Collins JA, Semaka A, Doty CN, et al. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. European Journal of Human Genetics. 2013;21(10).eng
dcterms.referencesKay C, Tirado-Hurtado I, Cornejo-Olivas M, Collins JA, Wright G, Inca- Martinez M, et al. The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. European Journal of Human Genetics. 2017;25(3).eng
dcterms.referencesKay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N, et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2016 Jul 19;87(3):282 8.eng
dcterms.referencesWarby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, et al. CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing Haplogroup. Am J Hum Genet. 2009;84(3).eng
dcterms.referencesFalush D. Haplotype Background, Repeat Length Evolution, and Huntington’s Disease. The American Journal of Human Genetics. 2009 Dec;85(6):939 42.eng
dcterms.referencesLee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, et al. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet. 2012;90(3).eng
dcterms.referencesLi XY, Li HL, Dong Y, Gao B, Cheng HR, Ni W, et al. Haplotype analysis encompassing HTT gene in Chinese patients with Huntington's disease. Eur J Neurol. 2020;27(2).eng
dcterms.referencesBlum D, Chern Y, Domenici MR, Buée L, Lin CY, Rea W, et al. The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease. J Caffeine Adenosine Res. 2018;8(2).eng
dcterms.referencesKoch ET, Raymond LA. Dysfunctional striatal dopamine signaling in Huntington's disease. Vol. 97, Journal of Neuroscience Research. 2019.eng
dcterms.referencesRosas-Arellano A, Estrada-Mondragón A, Maniellero C, Tejeda-Guzmán C, Castro M. The adjustment of y-aminobutyric acidA tonic subunits in Huntington's disease: From transcription to translation to synaptic levels into the neostriatum. Vol. 13, Neural Regeneration Research. 2018.eng
dcterms.referencesAlbin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10).eng
dcterms.referencesGalvan L, André VM, Wang EA, Cepeda C, Levine MS. Functional differences between direct and indirect striatal output pathways in Huntington's disease. Vol. 1, Journal of Huntington's Disease. 2012.eng
dcterms.referencesAugood SJ, Faull RLM, Love DR, Emson PC. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: A detailed cellular in situ hybridization study. Neuroscience. 1996;72(4).eng
dcterms.referencesJamwal S, Kumar P. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review. Curr Neuropharmacol. 2018;17(2).eng
dcterms.referencesCarmo C, Maia L, Lopes C, Rego AC. Mitochondrial Dysfunction in Huntington's Disease. In 2018. p. 59–83.eng
dcterms.referencesDubinsky JM. Towards an Understanding of Energy Impairment in Huntington's Disease Brain. Vol. 6, Journal of Huntington's Disease. 2017.eng
dcterms.referencesPuigivell M, Saavedra A, Pérez-Navarro E. Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies based on BDNF. Brain Pathology. 2016;26(6).eng
dcterms.referencesWalker FO. Huntington's disease. The Lancet. 2007 Jan;369(9557):218– 28.eng
dcterms.referencesRosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM. Complexity and heterogeneity: What drives the ever-changing brain in Huntington's disease? In: Annals of the New York Academy of Sciences. 2008.eng
dcterms.referencesValadão PAC, Santos KBS, Ferreira e Vieira TH, Macedo e Cordeiro T, Teixeira AL, Guatimosim C, et al. Inflammation in Huntington's disease: A few new twists on an old tale. Vol. 348, Journal of Neuroimmunology. 2020.eng
dcterms.referencesBates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nat Rev Dis Primers. 2015 Apr;23;1(1):15005.eng
dcterms.referencesGhosh R, Tabrizi SJ. Clinical features of huntington's disease. In: Advances in Experimental Medicine and Biology. 2018.eng
dcterms.referencesPaulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington's disease decades before diagnosis: The Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8).eng
dcterms.referencesTabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Ross RA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 2013;12(7).eng
dcterms.referencesVan Duijn E, Kingma EM, Van Der Mast RC. Psychopathology in verified Huntington's disease gene carriers. Journal of Neuropsychiatry and Clinical Neurosciences. 2007;19(4).eng
dcterms.referencesPaulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001;71(3).eng
dcterms.referencesReininghaus E, Lackner N. Relationship satisfaction and sexuality in Huntington's disease. In: Handbook of Clinical Neurology. 2015.eng
dcterms.referencesGrimaldi A, Veneziani I, Culicetto L, Quartarone A, Lo Buono V. Risk Factors and Interventions for Suicide in Huntington's Disease-A Systematic Review. J Clin Med. 2024 Jun 12;13(12):3437.eng
dcterms.referencesPaulsen JS, Hoth KF, Nehl C, Stierman L. Critical periods of suicide risk in Huntington's disease. American Journal of Psychiatry. 2005;162(4).eng
dcterms.referencesMcGarry A, McDermott MP, Kieburtz K, Fung WLA, McCusker E, Peng J, et al. Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial. Neurology. 2019;92(14).eng
dcterms.referencesPark S, Colwell CS. Do disruptions in the circadian timing system contribute to autonomic dysfunction in Huntingon’s disease? Vol. 92, Yale Journal of Biology and Medicine. 2019.eng
dcterms.referencesVan der Burg JMM, Weydt P, Landwehrmeyer GB, Aziz NA. Effect of Body Weight on Age at Onset in Huntington Disease. Neurol Genet. 2021;7(4).eng
dcterms.referencesLosekoot M, Van Belzen MJ, Seneca S, Bauer P, Stenhouse SAR, Barton DE. EMQN/CMGS best practice guidelines for the molecular genetic testing of huntington disease. European Journal of Human Genetics [Internet]. 2013;21(5):480 6. Available from: http://dx.doi.org/10.1038/ejhg.2012.200eng
dcterms.referencesJou YS, Myers RM. Evidence from antibody studies that the CAG repeat in the huntington disease gene is expressed in the protein. Hum Mol Genet. 1995;4(3).eng
dcterms.referencesAndrew SE, Goldberg YP, Theilmann J, Zeisler J, Hayden MR. A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. Hum Mol Genet. 1994 Jan 1;3(1):65 7.eng
dcterms.referencesPêcheux C, Mouret JF, Dürr A, Agid Y, Feingold J, Brice A, et al. Sequence analysis of the CCG polymorphic region adjacent to the CAG triplet repeat of the HD gene in normal and HD chromosomes. J Med Genet. 1995;32(5).eng
dcterms.referencesPramanik S, Basu P, Gangopadhaya PK, Sinha KK, Jha DK, Sinha S, et al. Analysis of CAG and CCG repeats in Huntingtin gene among HD patients and normal populations of India. European Journal of Human Genetics. 2000;8(9).eng
dcterms.referencesDe Luca A, Morella A, Consoli F, Fanelli S, Thibert JR, Statt S, et al. A Novel Triplet-Primed PCR Assay to Detect the Full Range of Trinucleotide CAG Repeats in the Huntingtin Gene (HTT). Int J Mol Sci. 2021 Feb 8;22(4):1689.eng
dcterms.referencesLosekoot M, van Belzen MJ, Seneca S, Bauer P, Stenhouse SAR, Barton DE. EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. European Journal of Human Genetics. 2013 May 19;21(5):480 6.eng
dcterms.referencesMargolis RL, Ross CA. Diagnosis of Huntington Disease. Clin Chem. 2003 Oct 1;49(10):1726 32.eng
dcterms.referencesBird TD. Outrageous Fortune: The Risk of Suicide in Genetic Testing for Huntington Disease. The American Journal of Human Genetics. 1999 May;64(5):1289 92.eng
dcterms.referencesCreighton S, Almqvist EW, MacGregor D, Fernandez B, Hogg H, Beis J, et al. Predictive, pre-natal and diagnostic genetic testing for Huntington’s disease: The experience in Canada from 1987 to 2000. Clin Genet. 2003;63(6).eng
dcterms.referencesReed SC. A short history of genetic counseling. Soc Biol. 1974 Dec 23;21(4):332 9.eng
dcterms.referencesNance MA. Genetic counseling and testing for Huntington’s disease: A historical review. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2017 Jan 13;174(1):75 92.eng
dcterms.referencesGoldman JS. Predictive genetic counseling for neurodegenerative diseases: Past, present, and future. Cold Spring Harb Perspect Med. 2020;10(7).eng
dcterms.referencesDufrasne S, Roy M, Galvez M, Rosenblatt DS. Experience over fifteen years with a protocol for predictive testing for Huntington disease. Mol Genet Metab. 2011;102(4).eng
dcterms.referencesGroves M. The highly anxious individual presenting for Huntington disease-predictive genetic testing: the psychiatrist’s role in assessment and counseling. In 2017. p. 99 105.eng
dcterms.referencesAlon I, Bussod I, Ravitsky V. Mapping ethical, legal, and social implications (ELSI) of preimplantation genetic testing (PGT). J Assist Reprod Genet. 2024;41(5).eng
dcterms.referencesHuibers AK Van T Spijker A. The autonomy paradox: Predictive genetic testing and autonomy: Three essential problems. Patient Educ Couns. 1998;35(1).eng
dcterms.referencesRoberts MC, Dotson WD, DeVore CS, Bednar EM, Bowen DJ, Ganiats TG, et al. Delivery of cascade screening for hereditary conditions: A scoping review of the literature. Health Aff. 2018;37(5).eng
dcterms.referencesSrinivasan S, Won NY, Dotson WD, Wright ST, Roberts MC. Barriers and facilitators for cascade testing in genetic conditions: a systematic review. Vol. 28, European Journal of Human Genetics. 2020.eng
dcterms.referencesSobel SK, Cowan DB. Impact of genetic testing for Huntington disease on the family system. Am J Med Genet. 2000;90(1).eng
dcterms.referencesTillerås KH, Kjoelaas SH, Dramstad E, Feragen KB, von der Lippe C. Psychological reactions to predictive genetic testing for Huntington’s disease: A qualitative study. J Genet Couns. 2020;29(6).eng
dcterms.referencesGargiulo M, du Montcel ST, Jutras MF, Herson A, Cazeneuve C, Durr A. A liminal stage after predictive testing for Huntington disease. J Med Genet. 2017;54(8).eng
dcterms.referencesMigliore S, Jankovic J, Squitieri F. Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon? Front Neurol. 2019 Apr 30;10.eng
dcterms.referencesAsociación Española Corea Huntington. https://www.e- huntington.es/opciones-reproductivas-en-la-enfermedad-de-huntington/ Planificación Familiar. Opciones Reproductivas en la Enfermedad de Huntington (Parte 2).eng
dcterms.referencesAsuragen®. AmplideX® PCR/CE HTT. Protocol Guide. Austin, TX, USA.; 2018. p. 1–28.eng
dcterms.referencesFuminaya A; García E; Gonzalez; Plata; Rodriguez. CALIDAD DE VIDA EN FAMILIAS CON ENFERMEDAD DE HUNTINGTON EN EL DEPARTAMENTO DEL ATLÁNTICO (1). [Trabajo no Publicado, Universidad Simón Bolívar]. 2023 Nov 21;1–59.spa
dcterms.referencesApolinário TA, da Silva I dos S, Agostinho L de A, Paiva CLA. Investigation of intermediate CAG alleles of the HTT gene in the general population of Rio de Janeiro, Brazil, in comparison with a sample of Huntington disease- affected families. Mol Genet Genomic Med. 2020 Apr 17;8(4).eng
dcterms.referencesRuiz de Sabando A, Urrutia Lafuente E, Galbete A, Ciosi M, García Amigót F, García Solaesa V, et al. Spanish HTT gene study reveals haplotype and allelic diversity with possible implications for germline expansion dynamics in Huntington disease. Hum Mol Genet. 2023 Mar 6;32(6):897– 906.eng
dcterms.referencesAziz NA, van Belzen MJ, Coops ID, Belfroid RDM, Roos RAC. Parent-of- origin differences of mutant HTT CAG repeat instability in Huntington's disease. Eur J Med Genet. 2011 Jul;54(4):e413–8.eng
dcterms.referencesWheeler VC, Persichetti F, McNeil SM, Mysore JS, Mysore SS, MacDonald ME, et al. Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet. 2007 Aug 23;44(11):695–701.eng
dcterms.referencesMroczek M. Comment on: "Somatic CAG repeat instability in intermediate alleles of the HTT gene and its potential association with a clinical phenotype" by Ruiz de Sabando et al. European Journal of Human Genetics. 2024 Jul 7;32(7):745–6.eng
dcterms.referencesSavitt D, Jankovic J. Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. J Neurol Sci. 2019 Jul;402:57 61.eng
dcterms.referencesEpping EA, Kim JI, Craufurd D, Brashers-Krug TM, Anderson KE, McCusker E, et al. Longitudinal Psychiatric Symptoms in Prodromal Huntington’s Disease: A Decade of Data. American Journal of Psychiatry. 2016 Feb;173(2):184 92eng
dcterms.referencesRaschka T, Li Z, Gaßner H, Kohl Z, Jukic J, Marxreiter F, et al. Unraveling progression subtypes in people with Huntington's disease. EPMA Journal. 2024 Jun 1;15(2):275–87.eng
dcterms.referencesPodvin S, Reardon HT, Yin K, Mosier C, Hook V. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration. Vol. 266, Journal of Neurology. Dr. Dietrich Steinkopff Verlag GmbH and Co. KG; 2019. p. 551–64.eng
dcterms.referencesPagan F, Torres-Yaghi Y, Altshuler M. The diagnosis and natural history of Huntington disease. In: Handbook of Clinical Neurology. Elsevier B.V.; 2017. p. 63–7.eng
dcterms.referencesCampo Oviedo M del C, Baute Gamez LE. Grupos vulnerables, la responsabilidad del Estado de garantizarles el derecho a la salud: Huntington en comunidades de la región Caribe de Colombia. Perfiles de las Ciencias Sociales. 2016 Jul–Dec;4(7):56–99. Universidad Juárez Autónoma de Tabasco (UJAT)spa
oaire.versioninfo:eu-repo/semantics/acceptedVersion
sb.programaMaestría en Genéticaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
PDF_Resumen.pdf
Tamaño:
235.37 KB
Formato:
Adobe Portable Document Format
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.93 KB
Formato:
Item-specific license agreed upon to submission
Descripción:

Colecciones